Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
19 mai 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
18 mai 2021 08h05 HE
|
Metacrine, Inc.
Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021Enrollment continuing for up to 180 patients, with full topline results expected to be reported...
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results
13 mai 2021 16h05 HE
|
Metacrine, Inc.
• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the...
Metacrine to Present at 2021 RBC Global Healthcare Conference
11 mai 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
05 avr. 2021 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
18 mars 2021 06h30 HE
|
Metacrine, Inc.
Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021 Topline Results from a Phase 2a Trial of MET409 in Combination with Empagliflozin...
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
11 mars 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
11 mars 2021 06h15 HE
|
Metacrine, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
09 mars 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference
02 mars 2021 06h30 HE
|
Metacrine, Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...